Next-generation CRISPR screens to fast-forward drug discovery

Our Technology

At Myllia, we perform functional genomics at scale in advanced cellular models to map the impact of thousands of genetic perturbations at single-cell resolution – a new paradigm to nominate the best possible targets for your drug discovery campaign.


CRISPR screens accelerate drug discovery across many therapeutic areas and help unravel gene regulatory networks in cancer cells and primary human T cells.

Drug target identification and validation

Mechanism of action (MoA) analysis

Identification of disease-associated gene function

Genetic screening 
for phenotypes of 
primary T cells

Genetic screening for primary T cell phenotypes

Genetic perturbation screens at single-cell resolution revolutionize the way we identify novel drug targets and gene regulatory networks involved in oncology and autoimmune disease.